Novo Nordisk has licensed an experimental once-weekly obesity pill from China’s Jiangsu Hengrui Pharmaceuticals, paying $300 million upfront with up to $2.3 billion more in development, regulatory and commercial milestones, plus royalties. The deal, announced on September 29, 2026, gives Novo exclusive rights to the drug, HRS-1596, everywhere outside mainland China, Hong Kong, Macau and Taiwan.
What HRS-1596 is
HRS-1596 is an oral small molecule that activates both the GLP-1 and GIP receptors — the same dual mechanism as Lilly’s blockbuster injection tirzepatide (Zepbound, Mounjaro), but in pill form. Its headline feature is once-weekly dosing. Today’s obesity pills, Novo’s own Wegovy pill and Lilly’s Foundayo, are taken every day. The drug is at an early stage: it is described as ready to enter Phase 1 testing in people, meaning there are not yet human efficacy data.
Why a weekly pill matters
Weekly injections became the standard for GLP-1 drugs partly because they are easy to remember. Daily pills removed the needle but brought back a daily routine — and in the Wegovy pill’s case, strict fasting rules. A pill that only has to be taken once a week would combine the convenience of a tablet with the simplicity of weekly dosing. It is a hard technical goal: a small molecule has to stay active in the body long enough to work for seven days without causing side effects when levels are highest. If HRS-1596 can do that, it could be a meaningful advance in a market where adherence strongly affects results.
Why small molecules are the prize
Semaglutide and tirzepatide are peptides, small proteins that are normally broken down in the gut. Making them work as pills requires workarounds: the Wegovy pill packs a large dose of semaglutide with an absorption enhancer and must be taken on an empty stomach. Small-molecule drugs like Lilly’s orforglipron (Foundayo) and HRS-1596 are built from scratch to act on the same receptors while being absorbed like ordinary pills. That brings practical advantages: they are generally cheaper and easier to manufacture at scale, do not need refrigeration, and avoid fasting rules. With demand for obesity drugs in the tens of millions of patients worldwide, manufacturing capacity and cost matter as much as efficacy, which is why nearly every major drugmaker is pursuing oral small-molecule options.
The rivalry behind the deal
Novo created the modern obesity-drug market with Wegovy, but Lilly has overtaken it. Lilly’s tirzepatide franchise generated roughly $15 billion in sales in the second quarter of 2026, about twice Novo’s semaglutide franchise at around $7.8 billion. In pills, Novo moved first with the Wegovy pill, which had a record-breaking launch, but Lilly’s Foundayo followed in April 2026 with the advantage of no food or water restrictions (we compared them here). A weekly dual-agonist pill is a way for Novo to aim past both current products rather than simply match them.
What the industry is looking for next
According to the deal announcement, Novo is targeting shifting treatment priorities: less frequent dosing, preserving lean muscle during weight loss, and demonstrating cardiovascular and other health benefits beyond the number on the scale. Those are the battlegrounds for the next generation of obesity drugs, which include triple-hormone injections such as Lilly’s retatrutide (explained here), amylin-based drugs, and longer-acting formulations.
The China connection
The deal is also part of a broader trend: Western drugmakers increasingly license early-stage molecules from Chinese biotechs, which have become fast, cost-efficient sources of new drug candidates. Hengrui, one of China’s largest drugmakers, has signed deals with Bristol Myers Squibb, GSK and Merck (MSD) across oncology, hematology and immunology, and has been active in obesity. For Western buyers, these deals offer a way to fill pipelines quickly; they also draw attention from US policymakers concerned about reliance on China for innovation.
What the numbers mean
A $300 million upfront payment for a drug that has not yet been tested in people is substantial, and reflects how valuable Novo believes a differentiated oral obesity drug could be. But most of the headline $2.6 billion is contingent: milestone payments are due only if the drug progresses through trials, wins approval and hits sales targets. Most early-stage drugs never reach the market, so the full amount is best read as a ceiling rather than an expected price. Royalties on any future sales would add to Hengrui’s return, and the company keeps the potentially large Chinese market for itself, where obesity rates are rising and domestic competition is intense.
What comes next
The immediate step is Phase 1 testing to establish safety, how the drug behaves in the body, and whether weekly dosing works in practice. Meaningful weight-loss data would come later, likely years away, and an approved weekly obesity pill is not expected soon. For patients, today’s options remain the approved weekly injections and daily pills. This is business news, not investment or medical advice.